ArticleBMJ open2024

A phase II double-blind multicentre, placebo-controlled trial to assess the efficacy and safety of alpelisib (BYL719) in paediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP): the SESAM study protocol.

Maxime Luu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.